Literature DB >> 25847167

Trihalomethane exposure and biomonitoring for the liver injury indicator, alanine aminotransferase, in the United States population (NHANES 1999-2006).

James B Burch1, Todd M Everson2, Ratanesh K Seth3, Michael D Wirth4, Saurabh Chatterjee5.   

Abstract

Exposure to trihalomethanes (or THMs: chloroform, bromoform, bromodichloromethane, and dibromochloromethane [DBCM]) formed via drinking water disinfection has been associated with adverse reproductive outcomes and cancers of the digestive or genitourinary organs. However, few studies have examined potential associations between THMs and liver injury in humans, even though experimental studies suggest that these agents exert hepatotoxic effects, particularly among obese individuals. This study examined participants in the National Health and Nutrition Examination Survey (1999-2006, N=2781) to test the hypothesis that THMs are associated with liver injury as assessed by alanine aminotransferase (ALT) activity in circulation. Effect modification by body mass index (BMI) or alcohol consumption also was examined. Associations between blood THM concentrations and ALT activity were assessed using unconditional multiple logistic regression to calculate prevalence odds ratios (ORs) with 95% confidence intervals (CIs) for exposure among cases with elevated ALT activity (men: >40IU/L, women: >30IU/L) relative to those with normal ALT, after adjustment for variables that may confound the relationship between ALT and THMs. Compared to controls, cases were 1.35 times more likely (95% CI: 1.02, 1.79) to have circulating DBCM concentrations exceeding median values in the study population. There was little evidence for effect modification by BMI, although the association varied by alcohol consumption. Among non-drinkers, cases were more likely than controls to be exposed to DBCM (OR: 3.30, 95% CI: 1.37, 7.90), bromoform (OR: 2.88, 95% CI: 1.21, 6.81), or brominated THMs (OR: 4.00, 95% CI: 1.31, 12.1), but no association was observed among participants with low, or moderate to heavy alcohol consumption. Total THM levels exceeding benchmark exposure limits continue to be reported both in the United States and globally. Results from this study suggest a need for further characterization of ALT activity and possibly other hepatic or metabolic diseases in populations with elevated drinking water THM concentrations.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Dibromochloromethane; Disinfection by-product; Metabolic syndrome; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2015        PMID: 25847167      PMCID: PMC4462191          DOI: 10.1016/j.scitotenv.2015.03.050

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  46 in total

1.  A comparison of disinfection by-products found in chlorinated and chloraminated drinking waters in Scotland.

Authors:  Emma H Goslan; Stuart W Krasner; Matthew Bower; Sophie A Rocks; Philip Holmes; Leonard S Levy; Simon A Parsons
Journal:  Water Res       Date:  2009-07-26       Impact factor: 11.236

Review 2.  The formation and control of emerging disinfection by-products of health concern.

Authors:  Stuart W Krasner
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2009-10-13       Impact factor: 4.226

3.  Disinfection by-products in drinking water and colorectal cancer: a meta-analysis.

Authors:  Md Bayzidur Rahman; Tim Driscoll; Christine Cowie; Bruce K Armstrong
Journal:  Int J Epidemiol       Date:  2010-02-05       Impact factor: 7.196

Review 4.  Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research.

Authors:  Susan D Richardson; Michael J Plewa; Elizabeth D Wagner; Rita Schoeny; David M Demarini
Journal:  Mutat Res       Date:  2007-09-12       Impact factor: 2.433

Review 5.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

6.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

7.  Elevated liver enzymes in individuals with undiagnosed diabetes in the U.S.

Authors:  Christie Y Jeon; Christian K Roberts; Catherine M Crespi; Zuo-Feng Zhang
Journal:  J Diabetes Complications       Date:  2013-05-14       Impact factor: 2.852

8.  Biomonitoring Equivalents (BE) dossier for trihalomethanes.

Authors:  Lesa L Aylward; Judy S LaKind; Sean M Hays
Journal:  Regul Toxicol Pharmacol       Date:  2008-05-22       Impact factor: 3.271

9.  Disinfection byproducts and bladder cancer: a pooled analysis.

Authors:  Cristina M Villanueva; Kenneth P Cantor; Sylvaine Cordier; Jouni J K Jaakkola; Will D King; Charles F Lynch; Stefano Porru; Manolis Kogevinas
Journal:  Epidemiology       Date:  2004-05       Impact factor: 4.822

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  2 in total

1.  Exposure to disinfection byproducts and risk of type 2 diabetes: a nested case-control study in the HUNT and Lifelines cohorts.

Authors:  Stephanie Gängler; Melanie Waldenberger; Anna Artati; Jerzy Adamski; Jurjen N van Bolhuis; Elin Pettersen Sørgjerd; Jana van Vliet-Ostaptchouk; Konstantinos C Makris
Journal:  Metabolomics       Date:  2019-04-08       Impact factor: 4.290

2.  Environmental risk factors for liver cancer and nonalcoholic fatty liver disease.

Authors:  Trang VoPham
Journal:  Curr Epidemiol Rep       Date:  2019-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.